Literature DB >> 27460861

A case of bullous pemphigoid ınduced by vildagliptin.

Havva Ozge Keseroglu1, Gamze Taş-Aygar1, Müzeyyen Gönül1, Ozay Gököz2, Sibel Ersoy-Evans3.   

Abstract

Bullous pemfigoid (BP), an autoimmune disorder, can also be induced by some medications. Vildagliptin is a new drug used to treat diabetes mellitus (DM). Recently, a few cases of vildagliptin-induced BP have been described in the literature. We report a patient with BP in which vildagliptin was thought to be as a possible causative agent. The awareness of BP development risk during gliptin therapy can prevent unnecessary usage of systemic drugs with serious side effects.

Entities:  

Keywords:  Bullous pemphigoid; gliptins; vildagliptin

Mesh：

Substances：

Year:  2016        PMID： 27460861     DOI： 10.1080/15569527.2016.1211670

Source DB:  PubMed          Journal:  Cutan Ocul Toxicol        ISSN： 1556-9527            Impact factor:   1.820


  7 in total

1.  Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

2.  Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.

Authors:  Olivier Gaudin; Vannina Seta; Marina Alexandre; Gérôme Bohelay; Françoise Aucouturier; Sabine Mignot-Grootenboer; Saskia Ingen-Housz-Oro; Céline Bernardeschi; Pierre Schneider; Benoît Mellottee; Frédéric Caux; Catherine Prost-Squarcioni
Journal:  Front Immunol       Date:  2018-05-24       Impact factor: 7.561

Review 3.  The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations.

Authors:  Khalaf Kridin; Ralf J Ludwig
Journal:  Front Med (Lausanne)       Date:  2018-08-20

4.  A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.

Authors:  Kentaro Izumi; Wataru Nishie; Mutsuo Beniko; Hiroshi Shimizu
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

Review 5.  Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin.

Authors:  Karim Chouchane; Giovanni Di Zenzo; Dario Pitocco; Laura Calabrese; Clara De Simone
Journal:  J Transl Med       Date:  2021-12-20       Impact factor: 5.531

6.  Linagliptin-Associated Alopecia and Bullous Pemphigoid.

Authors:  Ali Someili; Khalid Azzam; Mohannad Abu Hilal
Journal:  Eur J Case Rep Intern Med       Date:  2019-09-10

Review 7.  Bullous Pemphigoid: Trigger and Predisposing Factors.

Authors:  Francesco Moro; Luca Fania; Jo Linda Maria Sinagra; Adele Salemme; Giovanni Di Zenzo
Journal:  Biomolecules       Date:  2020-10-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.